Latest filing published 02 Dec 2022 for Sunshine Biopharma, Inc, €22k.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Camille Sebaaly: trading record in brief
This profile gathers the share dealings of Camille Sebaaly in Sunshine Biopharma, Inc, where the filings describe the role as finance chief. Between 22 April 2016 and 30 November 2022, the trades on record add up to 15 filings.
On the market, this insider has only ever bought: 2 purchases, €51k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 12 share grants. 2022 to date brings 2 purchases and no sales.
The latest filing, published on 2 December 2022, reports an open-market purchase of €22k in Sunshine Biopharma, Inc. Typically, a trade is published a median of 21 days after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Camille Sebaaly
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 30,000 shares@ US$0.763543.9% of flowCommon StockSEC:0001683168-22-008144:0Canonical exit: 28 Feb 2023 (T+90)
- 25,000 shares@ US$1.2256.1% of flowCommon StockSEC:0001683168-22-004178:0Canonical exit: 1 Sept 2022 (T+90)
2 of 2 declarations